After Apogee Therapeutics (APGE) reported a 52-week data update from the Phase 2a study of zumilokibart in atopic dermatitis, Stifel analyst Alex Thompson contends that these data further derisk zumilokibart’s path to approval with the potential for both differentiated dosing and efficacy. The firm maintains a Buy rating on Apogee shares, which are up $8.66, or 13%, to $74.70 in pre-market trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee data for zumilokibart in AD ‘a home-run success,’ says Citi
- Apogee Therapeutics Announces Positive Phase 2 APEX Maintenance Data
- Apogee Therapeutics announces maintenance data from Part A of APEX trial
- Apogee Therapeutics reports ‘positive’ results from Part A of Phase 2 APEX trial
- Block upgraded, Starbucks downgraded: Wall Street’s top analyst calls